Publications

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis  (2023)

Authors:
Lovato, Ester; Gangemi, Concetta; Krampera, Mauro; Visco, Carlo; Ferrarini, Isacco
Title:
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
Year:
2023
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
No
Name of journal:
FRONTIERS IN ONCOLOGY
ISSN of journal:
2234-943X
N° Volume:
13
Page numbers:
1-7
Keyword:
autoimmune complications; chronic lymphocytic leukemia; membranous glomerulonephritis; nephrotic syndrome; venetoclax
Short description of contents:
Membranous glomerulonephritis (MGN) is a rare extra-hematological autoimmune complication of chronic lymphocytic leukemia (CLL), clinically characterized by nephrotic-range proteinuria and, less frequently, renal failure. Because of the rarity of this condition, there is no standardized treatment. Chlorambucil and fludarabine-based regimens, possibly combined with rituximab, have been historically the most frequent therapeutic approaches, with renal response obtained in about two-third of the patients. However, responses are often transient and partial. Here we describe the first patient with rituximab-refractory, CLL-related MGN successfully treated with the Bcl-2 antagonist venetoclax. Nephrotic syndrome resolved as soon as three months after venetoclax initiation, with no unexpected toxicities. At the last follow-up, 17 months after venetoclax start, renal response persists, with proteinuria below 0.5 g/24 hours. This case suggests that targeted agents, particularly Bcl-2 antagonists, might be suitable options for patients with renal autoimmune disorders arising in the context of CLL.
Product ID:
134005
Handle IRIS:
11562/1095010
Last Modified:
October 19, 2024
Bibliographic citation:
Lovato, Ester; Gangemi, Concetta; Krampera, Mauro; Visco, Carlo; Ferrarini, Isacco, Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis «FRONTIERS IN ONCOLOGY» , vol. 132023pp. 1-7

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<back
Share